Given the unpredictable world COVID has created it’s nice to see that some predictability has returned. Per the earnings release from Tandem;
“We are reinstating the sales guidance we set at the beginning of 2020 based on the continued strong worldwide demand for our t:slim X2 insulin pump,” said Leigh Vosseller, executive vice president and chief financial officer. “While being mindful of the unpredictable nature of the current pandemic, our confidence in the remainder of this year is supported by the positive feedback from users of our Control-IQ technology and its scaling international launch, as well as . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.